RecoveryInjectableResearch Protocol

ARA-290 (Cibinetide) Dosage Chart

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B domain of erythropoietin, studied for tissue protection and neuropathic pain without EPO's hematopoietic effects (Brines et al., 2008; sarcoidosis small-fibre neuropathy trials).

AI-built tool. Cross-check critical values against authoritative sources before use.

Half-life

Short (~2 minutes systemic; effects outlast plasma levels)

Format

Injectable

Purity

≥99%

Protocols

3 variants

Buy ARA-290 (Cibinetide) — 50% off code ENHANCED View protocols

Research Protocols

Dosage Protocols

Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.

Protocol 1

Standard Research Protocol

4-12 weeks

Dose

2mg once daily (subcutaneous)

Duration

4-12 weeks

The dose used in small-fibre neuropathy research. Administered subcutaneously, typically in the evening.

Protocol 2

Elevated Research Protocol

4-8 weeks

Dose

4mg once daily

Duration

4-8 weeks

Upper end of the explored range. Cibinetide has a wide tolerability margin in trials, but keep durations bounded.

Protocol 3

Maintenance Protocol

Ongoing (cycled)

Dose

2mg 3-4 times per week

Duration

Ongoing (cycled)

Reduced-frequency dosing after an initial daily phase.

Mixing Math

Reconstitution

Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.

Vial size

10mg vial

BAC water

2ml bacteriostatic water

Concentration

5mg/ml (5000mcg/ml)

Dose / ml

2mg = 0.4ml · 4mg = 0.8ml

Syringe units

40 IU (2mg) · 80 IU (4mg) on a U-100 syringe

Need help converting different vial sizes? Use our reconstitution calculator to generate protocol-specific numbers instantly.

Frequently Paired

Common Stacks

Peptide

BPC-157

View guide

Peptide

KPV

View guide

Storage

Handling Notes

Lyophilized: 2-8°C preferred, -20°C for extended storage. Reconstituted: refrigerate at 2-8°C and use within about 28 days. Protect from light.

Research Considerations

Cautions

ARA-290 is a research compound not approved for human use. Source only COA-verified material.
Unlike EPO, ARA-290 is not intended to raise red cell mass, but hematologic parameters are still worth monitoring in extended research.
Human evidence is limited to small trials; there is no established therapeutic dose.

Ready to start your research

Get ARA-290 (Cibinetide) from Ascension Peptides

COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.

Buy ARA-290 (Cibinetide) now

Research use only. Not medical advice. Browse all dosage charts